Physician profile
Bo J Allaire
NPI 1235363862
$5,623.91
in general payments reported to CMS, 2019-2025
41 companies · $885 in 2025
The $885 reported for 2025 was more than what 88% of Addiction Medicine (Family Medicine) providers received nationally (typical 2025 total: $143).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $699 · 2020: $869 · 2021: $846 · 2022: $496 · 2023: $957 · 2024: $870 · 2025: $885.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,713.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,712.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,003.82 | 2021-2025 | Vraylar, Mavyret, Qulipta |
| Indivior INC. | $740.11 | 2019-2025 | Sublocade |
| Takeda Pharmaceuticals U.S.A., INC. | $610.28 | 2019-2025 | Trintellix |
| Alkermes, INC. | $433.57 | 2019-2025 | Vivitrol, Vivitrol |
| Allergan, INC. | $339.91 | 2019-2021 | |
| Eisai INC. | $291.44 | 2020-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $213.99 | 2020-2025 | Caplyta |
| Lilly USA, LLC | $179.99 | 2022-2025 | Mounjaro, Zepbound, Trulicity |
| Braeburn INC. | $175.61 | 2024-2025 | Brixadi |
| Merck Sharp & Dohme LLC | $168.69 | 2020-2023 | Belsomra |
| Bausch Health US, LLC | $161.75 | 2020-2022 | |
| Otsuka America Pharmaceutical, INC. | $158.16 | 2023-2025 | Rexulti, Abilify Maintena |
| Neuronetics, INC. | $115.25 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $76.99 | 2020-2021 | |
| Axsome Therapeutics, INC. | $71.46 | 2025 | Auvelity |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bo Allaire listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.